LowPulseSt Technology

Advantages

• Assurance of Clinical AccuracyReliable measurement accuracy is essential for clinicians to accurately assess a patient’s oxygenation status. LowPulseStr® arterial oxygen saturation technology has undergone rigorous clinical validation conducted by the International Hypoxia Laboratory (HLSZU), and its performance has been documented in clinical reports approved by the FDA, CE, and NMPA.The clinical evaluation was carried out on healthy adult volunteers who underwent controlled hypoxia testing. During the study, arterial blood samples were collected at regular intervals via an arterial catheter across multiple stable oxygen saturation phases. These samples were analyzed using a CO-oximeter to determine arterial oxygen saturation (SaO₂), which served as the reference standard.Simultaneously, pulse oximeter readings (SpO₂) were obtained using the LowPulseStr™ technology. Comparative analysis between the SpO₂ values and the reference SaO₂ values was conducted. The resulting SpO₂–SaO₂ dataset was subjected to statistical analysis, yielding a clinically accepted validation report confirming the accuracy and reliability of the technology, as illustrated in the figure below.

• Multi-Computing Engine and Anti-Interference TechnologyLowPulseStr® arterial oxygen saturation technology incorporates a tri-engine architecture, consisting of time-domain, frequency-domain, and decision-based algorithms to ensure high accuracy and reliability across a variety of clinical scenarios.·The time-domain algorithm is characterized by its real-time processing capabilities, delivering rapid SpO₂ calculations across diverse monitoring conditions. Its primary objective is to provide healthcare professionals with fast and accurate pulse oximetry readings for immediate clinical reference.·The frequency-domain algorithm offers strong anti-interference performance, making it particularly effective in complex clinical environments such as emergency care and neonatal monitoring. By filtering out motion artifacts and environmental noise, it enables reliable measurement results and supports clinicians in making precise assessments of patient status in challenging conditions.·The decision algorithm serves as an intelligent, autonomous evaluator of the final output. It integrates results from multiple physiological indicators and computational engines to deliver an optimized judgment, improving the accuracy of arterial oxygen saturation measurements and minimizing the risk of measurement failure in clinical applications.This multi-layered computing strategy is illustrated in the following figure, demonstrating how LowPulseStr® enhances measurement robustness and clinical reliability.

• Broad Clinical ApplicationLowPulseStr™ integrates wide-range measurement technology, significantly enhancing SpO₂ measurement accuracy across diverse patient populations and clinical conditions. Its adaptive multi-position gain control enables rapid optimization of signal quality upon entering the measurement state. Through dynamic gain switching via a multi-channel architecture, the system maintains optimal detection performance regardless of patient variability.This technology ensures high measurement reliability across a broad spectrum of skin tones— including light, medium, and dark pigmentation—as well as across various anatomical monitoring sites such as the forehead, earlobe, nose, fingers, and toes. Its versatility supports accurate oxygen saturation monitoring in neonatal, pediatric, and adult patients, meeting the demands of a wide range of clinical environments.

Clinical benefits

A clinical comparison between a standalone time-domain algorithm and LowPulseStr® technology was conducted under various patient movement conditions. The single time-domain algorithm exhibited a false alarm rate of approximately 30%, whereas LowPulseStr® reduced the false alarm rate to around 10%, demonstrating an improvement of over 20% (Figure 1, hereafter).Neonatal blood oxygen monitoring requires exceptional precision due to the thin skin of newborns, which allows light to penetrate easily and often leads to signal oversaturation, making accurate measurement difficult. LowPulseStr® demonstrates significantly improved performance in neonatal applications compared to conventional technology. Clinical feedback indicates that the original method has a measurement failure or error rate of approximately 10%, whereas LowPulseStr® reduces this rate to just 1%, ensuring more reliable and accurate SpO₂ monitoring for newborns (Figure 2, hereafter).In patients with darker skin tones, higher light intensity is required to achieve accurate measurements—particularly in cases of weak pulse signals, which are more prone to interference. Clinical studies have shown that the original technology had a false alarm rate of approximately 13% in dark-skinned patients. In contrast, LowPulseStr® technology reduced the false alarm rate to around 2.5%, significantly enhancing measurement reliability and overall clinical usability in this population (Figure 3, hereafter).

The normal human perfusion index (PI) is typically above 3%. When PI drops significantly, pulsations become very weak, making accurate SpO₂ measurement challenging.In low-perfusion conditions, eliminating noise artifacts is critical for reliable oximetry. LowPulseStr® signal processing technology employs adaptive filtering to effectively remove noise from weak signals, enabling accurate SpO₂ readings even when the perfusion index is as low as 0.05%. This ensures consistent performance in patients with compromised peripheral circulation.